ReviewPostepy dermatologii i alergologii2018
Cutaneous mastocytosis treatment: strategies, limitations and perspectives.
Review in Postepy dermatologii i alergologii, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 33 citations in OpenAlex.
- A successful treatment of urticaria pigmentosa with omalizumab in a pediatric patient: a case report.AME case reports · 2026Article
- A rare case of pediatric cutaneous bullous mastocytosis.JAAD case reports · 2025Article
- Large Congenital Cutaneous Mastocytoma Presenting With Recurrent Persistent Blistering: A Case Report.Cureus · 2023Article
- Recalcitrant Cutaneous Mastocytosis Treated With Genetically Informed Targeted Therapy: A Case Report.International journal of dermatology and venereology · 2023Article
- Comprehensive mastocytosis data analysis from a single center.BMC cancer · 2023Article
- Repositioning Drugs for Rare Diseases Based on Biological Features and Computational Approaches.Healthcare (Basel, Switzerland) · 2022Article
- Cutaneous mastocytosis in childhood.Allergologie select · 2022Review
- Mast cells: Therapeutic targets for COVID-19 and beyond.IUBMB life · 2021Review
- Role of Mast Cells in the Pathogenesis of Pruritus in Mastocytosis.Acta dermato-venereologica · 2021Article
- Molecular Background, Clinical Features and Management of Pediatric Mastocytosis: Status 2021.International journal of molecular sciences · 2021Review
- Long-Term Successful Treatment of Indolent Systemic Mastocytosis With Omalizumab.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2021Article
- Pediatric Mastocytosis: An Update.Mediterranean journal of hematology and infectious diseases · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mastocytosis is a rare myeloproliferative disease, characterized by excessive proliferation and accumulation of mast cells in the tissues. In cutaneous mastocytosis (CM), mast cells infiltration is limited to the skin, whereas in systemic mastocytosis (SM) internal organs are involved. The first-line treatment in CM is antimediator therapy (mainly H1 and H2 antihistamines) and short-term topical corticosteroids. Phototherapy is the second-line therapy which may be considered when antihistamines do not produce the expected improvement. New therapeutic options include omalizumab and KIT-targeting agents. Although the disappearance of skin lesions has been reported as a result of cytoreductive therapies in SM, the use of potentially toxic drugs in CM is not recommended. In all adults with mastocytosis and in pediatric patients with severe CM, a persistently elevated serum tryptase level and anaphylaxis in medical history, equipping with epinephrine autoinjector for use in case of anaphylaxis is recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.